Abiraterone Improves Outcomes in Metastatic Prostate Cancer Abiraterone Improves Outcomes in Metastatic Prostate Cancer
Abiraterone acetate plus prednisone improves outcomes in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC), regardless of baseline risk factors, according to results from the phase 3 COU-AA-302 study.Reuters Health Information
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Prednisone | Prostate Cancer | Study | Surgery